Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Account Payables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Change in Account Payables for 6 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 937.99% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 1019.21% increase, with the full-year FY2025 number at $3.3 million, up 1019.21% from a year prior.
  • Change in Account Payables was $1.9 million for Q4 2025 at Caribou Biosciences, up from $561000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.7 million in Q1 2024 to a low of -$2.4 million in Q2 2024.
  • A 5-year average of $156850.0 and a median of $164000.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 5275.68% in 2022, then surged 937.99% in 2025.
  • Caribou Biosciences' Change in Account Payables stood at $291000.0 in 2021, then crashed by 152.58% to -$153000.0 in 2022, then surged by 577.12% to $730000.0 in 2023, then plummeted by 131.37% to -$229000.0 in 2024, then soared by 937.99% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Change in Account Payables are $1.9 million (Q4 2025), $561000.0 (Q3 2025), and -$630000.0 (Q2 2025).